Kopran Limited · NSE:KOPRAN
Kopran — Q3 FY2024-25 Earnings Presentation
22 slides from Kopran's earnings presentation, Feb 11, 2025
Slide 1: Exchange filing cover letter for investor presentation
February 11, 2025 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol: KOPRAN Dear S
Slide 2: Corporate Presentation Q3 FY 2024-25
CORPORATE PRESENTATION Q3 FY 2024-25
Slide 3: Disclaimer
This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not
Slide 4: Performance
PERFORMANCE • Financial Highlights • Operational Performance • API • Formulation
Slide 5: Financial Highlights
Q-3 Q-2 Q-3 9M 9M PARTICULARS 2024-25 2024-25 2023-24 2024-25 2023-24 Revenue from Operations 16,624 15,156 15,892 45,724 42,851 EBITDA* 2,291 1,474 2,358 5,581 5,272 Finance Costs 216 223 224 657 601 Depreciation 400 385 327 1,173 929 Tax Expenses 346 226 471 936 1,003 Net Profit 1,040 738 1,579 2,
Slide 6: Operational Performance
OPERATIONAL ~ PERF ORMA NCE Kopran
Slide 7: APIs Operational Highlights: Segment-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX Q3 FY 2024-25 (Rs. In Lakhs) 9M 2024-25 (Rs. In Lakhs) 48 261 85 705 910 2 Anti- Diabetic 18 12 Anti- Diabetic 1885 806 Anti- Infective 3 3712 1234 Antibiotic-Urological 984 Antibiotic-Urological 1551 Anti- Infective 3817 Anti-Hypertensive 426 Ant
Slide 8: APIs Operational Highlights: Market-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX Q3 FY 2024-25 (Rs. In Lakhs) 9M 2024-25 (Rs. In Lakhs) 11220 3729 Export Sales Export Sales Local Sales Local Sales 5638 14849 Total Rs. 9,367 Lakhs Total Rs. 26,069 Lakhs
Slide 9: Formulations Operational Highlights: Region-wise Sales
Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP Q3 FY 2024-25 (Rs. In Lakhs) 9M 2024-25 (Rs. In Lakhs) 978 2457 5084 2044 Africa Africa 1657 519 CANADA CANADA Latem Latem Middle East and North Africa Middle East and North Africa 127 South Africa South Africa 67 633 Southeast Asia 18 S
Slide 10: Formulations Operational Highlights: Product-wise Revenue Mix
Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX Q3 FY 2024-25 (Rs. In Lakhs) 9M 2024-25 (Rs. In Lakhs) 3279 8867 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 3704 10225 Total Rs. 6,983 Lakhs Total Rs. 19,092 Lakhs
Slide 11: Company Overview
Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth
Slide 12: A Global Pharmaceutical Company
A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International 50+ Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations and app
Slide 13: API Vertical
API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT Anti-hypertensive Development, manufacturing and Atenolol Macrolide sale of diverse APIs and Advanced Neuromodulator Intermediates Cephalosporins - Non-Sterile & Sterile Urological One of the leaders in Atenolol
Slide 14: Formulations Vertical
FORMULATIONS PRODUCT SEGMENTS FORMULATIONS VERTICAL Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs PENICILLIN-BASED NON-PENICILLIN FINISHED ORAL BASED FINISHED Catering 100% export markets of both Regulated and
Slide 15: Strategic Imperatives
STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP Focus on R&D to develop niche, Development of intermediates for APIs high-value/high-volume APIs and intermediates Reducing dependence on China to move towards self sufficiency Capacity expansion Optimising operational cost
Slide 16: Regulatory Compliance
REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards FORMULATIONS ACCREDITATIONS of manufacturing and quality at its all plants API ACCREDITATIONS Approved by 15 countries including MHRA (UK), SAPHRA South The plant
Slide 17: Kopwan
~ Kopwan 900()!--====--=---=--=:.::.:_ _~- 00() ..,.___ OOo ----------
Slide 18: Snapshot
SNAPSHOT SALES/OTHER INCOME (Rs. LAKHS) EBITDA * (Rs. LAKHS) 8,739 8,178 62,920 7,441 55,405 50,980 48,813 45,876 5,581 5,180 36,013 4,696 2019-20 2020-21 2021-22 2022-23 2023-24 Dec-24 2019-20 2020-21 2021-22 2022-23 2023-24 Dec-24 891 859 6,161 6,103 657 5,096 624 608 512 2,723 2,887 2,120 2019-20
Slide 19: Building Shareholder Value Year on Year
BUILDING SHAREHOLDER VALUE YEAR ON YEAR EBITDA ( Rs. Lakhs) RoE ( % ) RoCE ( % ) 28.3 8,739 25.3 8,178 7,441 22.4 20.1 5,581 14.5 4,996 5,180 11.8 11.4 10.2 8.3 11 7.7 6.3 2019-20 2020-21 2021-22 2022-23 2023-24 Dec-24 2019-20 2020-21 2021-22 2022-23 2023-24 Dec-24 - Return on Networth/Equity - Retu
Slide 20: Financial summary (Rs. Lakhs)
(Rs. Lakhs) PARTICULARS Dec-2024 FY 2023-24 FY 2022-23 FY 2021-22 FY 2020-21 FY 2019-20 Equity Share Capital 4,825 4,821 4,821 4,821 4,325 4,325 Other Equity 46,058 44,303 39,104 37,796 20,178 14,643 Networth 50,883 49,125 43,925 42,617 24,503 18,968 Fixed Assets(net) 30,220 27,830 23,457 18,623 15,
Slide 21: Board of Directors
BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. ADARSH RAJENDRA SOMANI MRS. MAMTA BIYANI MR. NARAYAN ATAL EXECUTIVE VICE CHAIRMAN DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR DR. SIDDHAN SUBRAMANIAN DR. SUNITA BANERJI MR. SUSHEEL SOMANI MR. VARUN SURENDRA SOMANI INDEPENDENT DIRECTOR INDEPENDENT DIR
Slide 22: About Kopran Limited
ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New P